Over the past six months, AptarGroup's stock has been impacted by several events: the Q3 2026 Earnings Report on October 29, 2026, showed a 6% increase in reported sales to over $1 billion and 5% core sales growth, but adjusted EBITDA fell 2% to $217 million, and adjusted earnings per share were $1.52, down 6%, yet shares rose 5% on the news; the Pharma segment experienced emergency medicine destocking, which increased core sales by only 1% in Q3 2026, but would have risen 8% without this decline, which is expected to reduce full-year 2026 sales by approximately $65 million and impact Pharma's adjusted EBITDA margin; the company increased its quarterly dividend by 4.2% to $0.50 per share on October 29, 2026; AptarGroup lost control of its Russian unit on October 30, 2026, resulting in a $30 million cash loss and a booked loss following a Russian decree; Virginie Maes was appointed President of the Pharma Business on October 22, 2026; Aptar Pharma announced a collaboration with Massachusetts General Hospital on September 14, 2026, to establish a predictive, data-driven model for advancing nose-to-brain drug delivery; over the past 12 months, insider open-market trades were all sales, totaling $7.82 million (61.22K shares), with significant selling of approximately $7.72 million across fourteen transactions in the ninety days leading up to late October 2026; and 180 Wealth Advisors LLC increased its stake in AptarGroup by 149% during the third quarter of 2026, adding 12,104 shares.